Skip to main content
padlock icon - secure page this page is secure

Clinical application of dendritic cells in cancer vaccination therapy

Buy Article:

$52.00 + tax (Refund Policy)

Svane IM, Soot ML, Buus S, Johnson HE. Clinical application of dendritic cells in cancer vaccination therapy. APMIS 2003;111:818–34.

During the last decade use of dendritic cells (DC) has moved from murine and in vitro studies to clinical trials as adjuvant in cancer immunotherapy. Here they function as delivery vehicles for exogenous tumor antigens, promoting an efficient antigen presentation. The development of protocols for large-scale generation of dendritic cells for clinical applications has made possible phase I/II studies designed to analyze the toxicity, feasibility and efficacy of this approach. In clinical trials, DC-based vaccination of patients with advanced cancer has in many cases led to immunity and in selected patients to tumor regression. However, the majority of clinical trials are still in phase I, and interpretations are hampered by pronounced variation in study design related to technical aspects of DC preparation, treatment and schedule, monitoring of immune response, and clinically relevant endpoints, including toxicity and response evaluation. This paper aims to review the technical aspects and clinical impact of vaccination trials, focusing on the generation of DC-based vaccines, evaluation of immunologic parameters and design of clinical trials necessary to meet the need for good laboratory and clinical practice.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Dendritic cell; T cell; cancer vaccine; clinical trial

Document Type: Research Article

Affiliations: 1: Institute of Medical Microbiology and Immunology, Panum Institute, University of Copenhagen, Copenhagen, Denmark 2: Department of Haematology, Herlev Hospital, University of Copenhagen, Herlev

Publication date: July 1, 2003

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more